Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Bioness Receives FDA Clearance for myBioness™ iOS app for mobile control of the L300 Go™ System

Bioness,Inc.
Posted on: 26 Mar 18
Bioness Receives FDA Clearance for myBioness™ iOS app for mobile control of the L300 Go™ System The myBioness is the first mobile app designed to provide control of the L300 Go™ System.

PR Newswire

VALENCIA, Calif., March 26, 2018

VALENCIA, Calif., March 26, 2018 /PRNewswire/ -- Bioness, Inc., the leading provider of cutting-edge, clinically supported rehabilitation therapies, today announced that it received clearance from the U.S. Food and Drug Administration (FDA) for the myBionessTM mobile app for use with the L300 Go™ System.

The new myBioness™ mobile iOS application allows home users to control their L300 Go system including ability to change stimulation modes between gait and training along with adjusting personal pre-set intensities to meet their daily activity demands. The app has been designed to keep users engaged in the rehabilitation process and motivated to meet their recovery goals with ability to track activity, set personal goals and review their progress over time using dynamic reporting capabilities.

Gait movement disorders, such as foot drop and knee instability, are often associated with an upper motor neuron disease such as stroke and multiple sclerosis as well as injuries to the brain and spinal cord. Individuals with an impaired gait have less control over their lower extremity muscles and are at an increased risk for falls. The L300 Go is the first functional electrical stimulation (FES) system to offer 3D motion detection of gait events and muscle activation using data from a 3-axis gyroscope and accelerometer.  Patient movement is monitored in all three kinematic planes and stimulation is deployed precisely when needed during the gait cycle.  An adaptive, learning algorithm accommodates changes in gait dynamics, and a high speed processor that deploys stimulation within 10 milliseconds of detecting a valid gait event.  This rapid, reliable response is critical and supports user confidence.

"Technological innovations including 3D motion detection and multi-channel stimulation work together to improve treatment efficiency and promote patient mobility," said Todd Cushman, President and CEO of Bioness. "At Bioness, we are focused on improving the lives of patients through technology and are proud to add the myBioness mobile application to the L300 Go portfolio of products."

The L300 Go System was cleared by the U.S. Food and Drug Administration on January 27, 2017 with formal approval of the upgraded mobile application clearance dated March 9, 2018.  The system is indicated to provide ankle dorsiflexion in adult and pediatric individuals with foot drop and/or assist knee flexion or extension in adult individuals with muscle weakness related to upper motor neuron disease/injury (e.g., stroke, damage to pathways to the spinal cord). The L300 Go System electrically stimulates muscles in the affected leg to provide ankle dorsiflexion of the foot and/or knee flexion or extension; thus, it also may improve the individual's gait.

Bioness will begin commercial release of the myBionessTM mobile app in the spring of 2018.   The L300 Go Systems are commercially available since the summer of 2017.

About  Bioness, Inc.  
Bioness is the leading provider of innovative technologies helping people regain mobility and independence. Bioness solutions include implantable and external neuromodulation systems, robotic systems and software based therapy programs providing functional and therapeutic benefits for individuals affected by pain, central nervous system disorders and orthopedic injuries. Currently, Bioness offers six medical devices within its commercial portfolio which are distributed and sold on five continents and in over 25 countries worldwide. Our technologies have been implemented in the most prestigious and well-respected institutions around the globe with approximately 90% of the top rehabilitation hospitals in the United States currently using one or more Bioness solution.  Bioness has a singular focus on aiding large, underserved customer groups with innovative, evidence-based solutions and we will continue to develop and make commercially available new products that address the growing and changing needs of our customers. Individual results vary. Consult with a qualified physician to determine if this product is right for you. Contraindications, adverse reactions and precautions are available online at www.bioness.com.  

Media Relations Contact Information
Next Step Communications 
bioness@nextstepcomms.com 
781.326.1741

All trademarks and copyrights here within are © Bioness. | www.bioness.com | Rx Only for applicable products.

 

View original content with multimedia:http://www.prnewswire.com/news-releases/bioness-receives-fda-clearance-for-mybioness-ios-app-for-mobile-control-of-the-l300-go-system-300619265.html

SOURCE Bioness, Inc.

PR Newswire
www.prnewswire.com

Last updated on: 26/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.